SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. It also performs clinical development in order to secure proof-of-concept such as clinical relevance. The company was founded by Søren Nielsen on April 12, 2016 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company